To learn more, give feedback, and participate, please contact:

Jayne Christen, Ph.D. Project Manager, Vaccine, Immunity, and Cancer Directorate

Subscribe to SeroNews

Subscribe

SeroNews

SeroNews is the quarterly newsletter from the NCI Serological Sciences Network. Each edition includes clinical and translational serology highlights.

This newsletter will be published every three to four months and is intended to summarize key priorities, perspectives, and events of a very engaged and enthusiastic team of scientists, clinicians, public health specialists, regulators, and policymakers collaborating on diverse COVID-19 response efforts to fight the spread of the virus. We hope our collaborative work will fully leverage the power of serology, new scientific findings, and technical tools to benefit public health and ensure a better and healthier world.

Fall 2021

News

Past events

Each quarter, SeroNet is dedicated to inviting speakers from academia, government, and industry. These meetings for SeroNet members focus on topics relevant to research goals and clinical applications.

 

Monthly Meetings

The Task Force members take basic research findings from SeroNet and discuss how to translate them to clinical applications.

Month

Topic

Speakers

March Clinical and Public Health Applications of SARS-CoV-2 Antibody Testing – Regulatory and Policy Perspectives
  • Dr. Ryan Karsner, Medical Officer, Division of Microbiology Devices, FDA
  • Dr. Adi Gundlapalli, Chief Public Health Informatics Officer, CSELS, CDC
April The Role of IDSA in Creating Guidelines for SARS-CoV-2 Serology Dr. Mark Loeb, McMaster University
May Overview of the COVID-19 Immunity Task Force Efforts in Canada Dr. Timothy Evans, CITF Executive Director, McGill University
  SARS-CoV-2 Serology and Correlates of Protection Studies at BARDA Dr. Allison Totura, Division of Nonclinical Development, BARDA
June COVID-19 Vaccination in Cancer Patients Dr. Joshua Hill, Vaccine & Infectious Disease and Clinical Research Divisions, Fred Hutchinson Cancer Research Center
July The UK COV-BOOST Trial Dr. Saul Faust, Director, Southampton NIHR Wellcome Trust Clinical Research Facility, University of Southampton
  The OCTAVE/OCTAVE DUO Trial Dr. Carl Goodyear, Professor of Translational Immunology, University of Glasgow
August COVID and Cancer: Future Preventive Strategies Dr. Amit Verma, Associate Director, Translational Science, Albert Einstein Cancer Center
  COVID-19 Vaccine and Patients with Cancer Participating in Oncology Clinical Trials Dr. Vivek Subbiah, Executive Director, Medical Oncology Research, MD Anderson Cancer Network
September Creation of a High-Throughput COVID Sequencing Pipeline Dr. Lax Iyer and Dr. Stan Letovsky, Center of Excellence for Data Sciences, AI and Bioinformatics, Labcorp
  The Status of SARS-CoV-2 Variant Reporting in Public Health Laboratories Ms. Kelly Wroblewski, Director of Infectious Disease Programs, Association of Public Health Laboratories

 

Focus group meetings

Subsets of the Task Force gather to focus on a topic.

Month

Topic

Speakers

March Do we have enough data-based evidence to develop two antibody-related guidelines (vaccinated/unvaccinated)?: Update to CDC Interim Guidelines for COVID-19 Antibody Testing Dr. Adi Gundlapalli, Chief Public Health Informatics Officer, CSELS, CDC
  What is the Status of EUA for Quantitative Serology and Neutralization Assays? Dr. Ryan Karsner, Medical Officer, Division of Microbiology Devices, FDA
  What are the Plans for Bridging Vaccine Efficacy with Serology? Dr. Ruben Donis, Influenza and Emerging Infectious Diseases Division, BARDA
July Regulatory Pathway for Serology Test Immunity and Protection Claims Dr. Timothy Stenzel, Director of the Office of In Vitro Diagnostics and Radiological Health, FDA (CDRH)
  COVID-19 Vaccine Responses in Immunocompromised Patients: State of the Evidence and Future Directions Dr. Ghady Haidar, Director of Research, Bone Marrow Transplant/Hematologic Malignancy ID, University of Pittsburgh School of Medicine
August A Correlate of Protection for SARS-CoV-2 Dr. Florian Krammer, Professor, Vaccinology, Department of Microbiology, Icahn School of Medicine at Mount Sinai
  The Relationship between Neutralizing Antibodies and Protection from SARS-CoV-2 Infection Dr. Miles Davenport, Theme Lead, Basic Science and Pathogenesis Team, and Program Head, Infection Analytics Program, Kirby Institute, University of New South Wales
September Regeneron’s Approach to Tackling COVID Now and in the Future Dr. George Yancopoulos, Scientific Founder, President, and Chief Scientific Officer, Regeneron
  Anticoagulation in Patients Hospitalized with COVID-19: Evidence Review and Design of FREEDOM COVID Anticoagulation Trial Dr. Valentin Fuster, Physician-in-Chief, The Mount Sinai Hospital and Director, Mount Sinai Heart

 

Round table meetings

Open to all SeroNet members, these meetings invite speakers from industries to address relevant topics.

Month

Topic

Speakers

February Serology Assays for Vaccine Trials, Selection of Antibody Treatments and Serosurveillance: Are we there yet?
  Serology Science of Mount Sinai COVID-19 Platforms: Clinical Significance and Commercial Tests Dr. Florian Krammer and Dr. Erik Lium, Icahn School of Medicine at Mount Sinai
  Clinical Utility of Commercially Available SARS-CoV-2 Serology Testing Dr. James Freeman, Siemens
  Advanced Serology Testing for SARS-CoV-2 and Other Pathogens: Vaccine Development, Seroprevalence Surveys and Clinical Studies Dr. Jim Wilbur, Meso Scale Discovery
  SARS-CoV-2 Antibody Testing in a Large Commercial Lab: Where are we and where are we going? Dr. Nigel Clarke, Quest Diagnostics
April Impact of Viral Variants and Integration of Sequencing Efforts with Serology Data
  SARS-CoV-2 Genomics at NIAID Dr. Liliana Brown, Director, Office of Genomics and Advanced Technologies, NIAID
  Standards and Translational Science for SARS-CoV-2 Measurements Dr. Marc Salit, Director, Joint Initiative for Metrology in Biology, SLAC National Accelerator Laboratory, Stanford University
June Vaccination in Cancer Patients and Immunocompromised Individuals
  Variable Responses to COVID-19 Vaccination in Myeloma Dr. Samir Parekh, Hematology-Oncology and Oncological Sciences, Mount Sinai
  Immunogenicity of COVID-19 mRNA Vaccines in Immunosuppressed Patients with Autoimmune Disease Dr. Alfred Kim, Director, Washington University Lupus Clinic, Washington University School of Medicine
  SARS-CoV-2 Vaccine Safety and Immunogenicity in Solid Organ Transplant Recipients Dr. Andrew Karaba, Transplant/Oncology Infectious Diseases, JHU School of Medicine
August Protection against New Variants by COVID-19 Vaccines: Where are we now and where do we need to go?
  VACCINES WORK: A Newcastle Disease Virus-Vectored SARS-CoV-2 Spike Vaccine

Dr. Peter Palese, Horace W. Goldsmith Professor and Chair, Department of Microbiology, Icahn School of Medicine at Mount Sinai

  Update on Effectiveness of BNT162b2 against SARS-CoV-2 Variants Dr. Kena Swanson, Senior Director, Viral Vaccines, Pfizer
  mRNA-1273 Effectiveness against Variants Dr. Randall Hyer, SVP, Global Medical Affairs, Moderna